Peptide Biologix
Compound index
The atlas

GHRP-6 Technical Specification Sheet

GH / GHRH Axis · MW 873.01 g/mol · Growth Hormone Releasing Peptide-6 · First-generation hexapeptide GH secretagogue with secondary CD36 receptor interaction; GHRP-6 remains listed in Category 2 (503B) on FDA’s compounding bulk drug substances page current as of April 22, 2026.

Botanical plate of a young plant with its branching root system exposed
Plate 11GHRP-6
Primary Amino Acid Sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

Molecular Properties

Parameter Value
Chemical Name Growth Hormone Releasing Peptide-6
Amino Acid Sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
Molecular Formula C₄₆H₅₆N₁₂O₆
Molecular Weight 872.44 g/mol
CAS Number 87616-84-0
Sequence Length 6 amino acids (synthetic hexapeptide with D-amino acids)
Receptor Target Growth Hormone Secretagogue Receptor 1a (GHS-R1a) / Ghrelin receptor; CD36 (additional effects)

Physical Properties

Property Specification
Appearance White to off-white lyophilized powder
Solubility Soluble in water or aqueous buffer at ≥1 mg/mL; pH 5.0-7.0
pH (1% solution) 5.0 - 7.0
Hygroscopicity Low to moderate; standard desiccated storage
Solution Stability Stable at 4°C for 10-14 days; D-amino acids enhance stability

Analytical Specifications

Test Specification
HPLC Purity ≥98.0%
Mass Spectrometry Confirmed [M+H]⁺ = 872.44 ± 0.5 Da
Peptide Content ≥95% (by amino acid analysis)
Endotoxin Level <1.0 EU/mg
Acetate Content ≤5%
TFA Content ≤0.1%
Water Content ≤6% (Karl Fischer)

Storage Parameters

Condition Specification
Lyophilized Storage -20°C, desiccated
Lyophilized Shelf Life 24-36 months when stored properly
Reconstituted Storage 2-8°C for up to 14 days; -20°C for up to 3 months
Analytical Stock Preparation Dissolve in sterile water or aqueous buffer with gentle vortexing for 30 seconds
Freeze-Thaw Cycles Tolerates up to 5 cycles; D-amino acids provide stability
Light Sensitivity Low; standard laboratory storage acceptable

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Experimental Model Published Concentration / Regimen Exposure Schedule Administration Context
In Vitro Pituitary Cell Assays 10-1000 nM Acute stimulation (30 min to 2 hours) Culture media
Small Animal Models (Rodent) 50-500 μg/kg 1-3x daily SC or IV in rodent models
GH Secretion Studies (Rodent) 100-300 μg/kg Single dose or repeated for 7-28 days SC in rodent models
Appetite/Feeding Studies (Rodent) 200-800 μg/kg 30-60 min before feeding measurements SC or IP in rodent models

Note: Concentrations and animal regimens summarized above are for research reference only. GHRP-6 is intended for laboratory research and is notable for strong appetite-stimulating effects among GHRPs.

Key Research Studies

Literature summary of published study doses, routes, and schedules.
Year Study Focus Key Findings
1984 Initial discovery and GH-releasing activity First synthetic hexapeptide GHRP identified by Bowers group; demonstrated potent GH release with EC₅₀ of 0.2-2 nM in vitro; 100-1000x more potent than GHRH on molar basis
1996 Appetite stimulation and food intake GHRP-6 (300-600 μg/kg SC) increased food intake by 60-100% within 2 hours in animal models; effect mediated via hypothalamic NPY/AgRP neurons; strongest orexigenic effect among early GHRPs
2002 CD36 receptor interaction Identified CD36 (fatty acid translocase) as secondary target for GHRP-6; mediated anti-inflammatory and cardioprotective effects independent of GHS-R1a; Ki ~100-500 nM at CD36
2008 Dual receptor mechanism characterization GHRP-6 effects dissected: GH release via GHS-R1a (blocked by [D-Lys3]-GHRP-6); appetite via GHS-R1a; wound healing and fibrosis effects via CD36; demonstrated unique dual-target pharmacology

Mechanism of Action

Biological Pathway Description
GHS-R1a Activation (Primary) Binds ghrelin receptor (GHS-R1a), Gq-coupled GPCR; high affinity (Kd ~0.5-5 nM); stimulates GH release and appetite
GH Secretion Activates pituitary somatotrophs → PLC/PKC → Ca²⁺ mobilization → GH release; peak GH at 20-40 minutes post-stimulus; pulsatile pattern
Appetite Stimulation Activates arcuate NPY/AgRP neurons; strongest hunger effect in GHRP family; increases ghrelin-like orexigenic signaling; food intake peaks 1-3 hours post-stimulus in rodent models
CD36 Receptor Effects Binds CD36 (moderate affinity); anti-inflammatory actions; modulates fatty acid uptake; cardioprotective and wound healing properties in preclinical models
Half-Life 20-30 minutes (IV/SC); D-amino acids provide peptidase resistance

Comparative Analysis: GHRP-6 vs GHRP-2

Parameter GHRP-6 GHRP-2
Sequence Position 1 L-His D-Ala
Sequence Position 2 D-Trp D-2-Nal
GH Release Potency High (EC₅₀ ~0.2-2 nM) High (EC₅₀ ~0.1-1 nM)
Appetite Stimulation Very strong (+60-100%) Strong (+40-60%)
CD36 Interaction Yes (moderate affinity) Minimal
Clinical Development Research tool Advanced to diagnostic human trials

Quality Control Parameters

Test Method Acceptance Criteria
Appearance (visual) White to off-white powder; no aggregation or discoloration
Chiral Purity D-amino acids at positions 2 and 5 confirmed; >98% correct stereochemistry
RP-HPLC (purity) Main peak ≥98.0%; no single impurity >0.5%
ESI-MS (identity) [M+H]⁺ = 872.44 ± 0.5 Da confirmed
Biological Activity ≥85% potency vs reference in GH release assay

Structure-Activity Relationship

Position Amino Acid Structural Role
1 L-His N-terminal; imidazole ring; pH-dependent charge; distinguishes from GHRP-2
2 D-Trp Critical for receptor binding; D-configuration essential for activity and stability
3 L-Ala Conformational spacer; small side chain
4 L-Trp Essential for GHS-R1a activation; indole ring interactions
5 D-Phe Receptor selectivity; D-configuration prevents degradation
6 L-Lys-NH₂ C-terminal; positive charge; amidation absolutely required

Reported Biological Effects

Effect Category Observed Changes Timeframe
GH Secretion Peak GH increase 5-15x baseline; occurs 20-40 min post-stimulus; duration 1-2 hours Acute (minutes to hours)
IGF-1 Elevation Increased 30-60% with repeated dosing in animal studies; cumulative with chronic administration 7-14 days
Appetite/Food Intake Increased food intake 60-100% in rodent models; strongest effect in GHRP class; peak 1-3 hours Acute (1-4 hours)
Anti-inflammatory Reduced inflammatory markers; CD36-mediated effects; cardioprotective/wound healing effects in animal models 24-72 hours

Regulatory & Compounding Status (April 2026)

On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, GHRP-6 is listed in Category 2 under 503B (bulk drug substances that raise significant safety risks in compounding). GHRP-6 is an unapproved investigational compound and is not approved by the U.S. FDA for human or veterinary therapeutic use. This monograph is intended strictly for laboratory research.

External References

  1. Bowers CY, et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology. 1981;108(3):1070-6. https://pubmed.ncbi.nlm.nih.gov/6109621/
  2. Demers A, et al. Growth hormone-releasing peptides: a potential multifaceted treatment for the heart. Recent Pat Cardiovasc Drug Discov. 2011;6(1):52-9. https://pubmed.ncbi.nlm.nih.gov/21208158/
  3. National Center for Biotechnology Information. PubChem Compound Summary for GHRP-6. https://pubchem.ncbi.nlm.nih.gov/compound/GHRP-6